Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities

View Full Paper
Ask AI
Bookmark
Share

Authors

NGNehemias GuevaraSKSyeda Ashna Fatima KamalNCNoemy Coreas

Discussion

Loading...

Member takes

Overview

Real-world data reveals CAR-T therapy reduces 5-year mortality compared to teclistamab in RRMM, indicating treatment disparities.

Key Points

  • To compare the effectiveness of CAR-T cell therapy and teclistamab in relapsed/refractory multiple myeloma patients, focusing on survival outcomes.
  • Utilized TriNetX US Collaborative Network data from 65 healthcare organizations
  • Identified adult RRMM patients treated with CAR-T (n=1,109) or teclistamab (n=951)
  • Employed a 1:1 propensity score matching approach resulting in 695 matched patients per group
  • CAR-T therapy associated with 16.8% 5-year mortality compared to 23.3% for teclistamab
  • Hazard ratio for mortality was 0.50, showing a 50% reduction in risk with CAR-T
  • Disparities in treatment allocation observed, with White patients more likely to receive CAR-T

Cite This Study

Guevara et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7cbhttps://doi.org/10.1182/blood-2025-2206
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma.2026
  2. 2Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  3. 3Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.2026
  4. 4Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort2026
  5. 5Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025